Research ExplorerPublicationsPlasma pTau-217 and N-terminal tau (NTA) enhance sensitivity...

Plasma pTau-217 and N-terminal tau (NTA) enhance sensitivity to identify tau PET positivity in amyloid-β positive individuals

Standard

Plasma pTau-217 and N-terminal tau (NTA) enhance sensitivity to identify tau PET positivity in amyloid-β positive individuals. / Woo, Marcel S; Tissot, Cécile; Lantero-Rodriguez, Juan; Snellman, Anniina; Therriault, Joseph; Rahmouni, Nesrine; Macedo, Arthur C; Servaes, Stijn; Wang, Yi-Ting; Arias, Jaime Fernandez; Hosseini, Seyyed Ali; Chamoun, Mira; Lussier, Firoza Z; Benedet, Andrea L; Ashton, Nicholas J; Karikari, Thomas K; Triana-Baltzer, Gallen; Kolb, Hartmuth C; Stevenson, Jenna; Mayer, Christina; Kobayashi, Eliane; Massarweh, Gassan; Friese, Manuel A; Pascoal, Tharick A; Gauthier, Serge; Zetterberg, Henrik; Blennow, Kaj; Rosa-Neto, Pedro.

In: ALZHEIMERS DEMENT, Vol. 20, No. 2, 02.2024, p. 1166-1174.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Woo, MS, Tissot, C, Lantero-Rodriguez, J, Snellman, A, Therriault, J, Rahmouni, N, Macedo, AC, Servaes, S, Wang, Y-T, Arias, JF, Hosseini, SA, Chamoun, M, Lussier, FZ, Benedet, AL, Ashton, NJ, Karikari, TK, Triana-Baltzer, G, Kolb, HC, Stevenson, J, Mayer, C, Kobayashi, E, Massarweh, G, Friese, MA, Pascoal, TA, Gauthier, S, Zetterberg, H, Blennow, K & Rosa-Neto, P 2024, 'Plasma pTau-217 and N-terminal tau (NTA) enhance sensitivity to identify tau PET positivity in amyloid-β positive individuals', ALZHEIMERS DEMENT, vol. 20, no. 2, pp. 1166-1174. https://doi.org/10.1002/alz.13528

APA

Woo, M. S., Tissot, C., Lantero-Rodriguez, J., Snellman, A., Therriault, J., Rahmouni, N., Macedo, A. C., Servaes, S., Wang, Y-T., Arias, J. F., Hosseini, S. A., Chamoun, M., Lussier, F. Z., Benedet, A. L., Ashton, N. J., Karikari, T. K., Triana-Baltzer, G., Kolb, H. C., Stevenson, J., ... Rosa-Neto, P. (2024). Plasma pTau-217 and N-terminal tau (NTA) enhance sensitivity to identify tau PET positivity in amyloid-β positive individuals. ALZHEIMERS DEMENT, 20(2), 1166-1174. https://doi.org/10.1002/alz.13528

Vancouver

Woo MS, Tissot C, Lantero-Rodriguez J, Snellman A, Therriault J, Rahmouni N et al. Plasma pTau-217 and N-terminal tau (NTA) enhance sensitivity to identify tau PET positivity in amyloid-β positive individuals. ALZHEIMERS DEMENT. 2024 Feb;20(2):1166-1174. https://doi.org/10.1002/alz.13528

Bibtex

@article{80d50cd97635434db57abbcded7b6a1d,
title = "Plasma pTau-217 and N-terminal tau (NTA) enhance sensitivity to identify tau PET positivity in amyloid-β positive individuals",
abstract = "INTRODUCTION: We set out to identify tau PET-positive (A+T+) individuals among amyloid-beta (Aβ) positive participants using plasma biomarkers.METHODS: In this cross-sectional study we assessed 234 participants across the AD continuum who were evaluated by amyloid PET with [18 F]AZD4694 and tau-PET with [18 F]MK6240 and measured plasma levels of total tau, pTau-181, pTau-217, pTau-231, and N-terminal tau (NTA-tau). We evaluated the performances of plasma biomarkers to predict tau positivity in Aβ+ individuals.RESULTS: Highest associations with tau positivity in Aβ+ individuals were found for plasma pTau-217 (AUC [CI95% ] = 0.89 [0.82, 0.96]) and NTA-tau (AUC [CI95% ] = 0.88 [0.91, 0.95]). Combining pTau-217 and NTA-tau resulted in the strongest agreement (Cohen's Kappa = 0.74, CI95% = 0.57/0.90, sensitivity = 92%, specificity = 81%) with PET for classifying tau positivity.DISCUSSION: The potential for identifying tau accumulation in later Braak stages will be useful for patient stratification and prognostication in treatment trials and in clinical practice.HIGHLIGHTS: We found that in a cohort without pre-selection pTau-181, pTau-217, and NTA-tau showed the highest association with tau PET positivity. We found that in Aβ+ individuals pTau-217 and NTA-tau showed the highest association with tau PET positivity. Combining pTau-217 and NTA-tau resulted in the strongest agreement with the tau PET-based classification.",
author = "Woo, {Marcel S} and C{\'e}cile Tissot and Juan Lantero-Rodriguez and Anniina Snellman and Joseph Therriault and Nesrine Rahmouni and Macedo, {Arthur C} and Stijn Servaes and Yi-Ting Wang and Arias, {Jaime Fernandez} and Hosseini, {Seyyed Ali} and Mira Chamoun and Lussier, {Firoza Z} and Benedet, {Andrea L} and Ashton, {Nicholas J} and Karikari, {Thomas K} and Gallen Triana-Baltzer and Kolb, {Hartmuth C} and Jenna Stevenson and Christina Mayer and Eliane Kobayashi and Gassan Massarweh and Friese, {Manuel A} and Pascoal, {Tharick A} and Serge Gauthier and Henrik Zetterberg and Kaj Blennow and Pedro Rosa-Neto",
note = "{\textcopyright} 2023 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.",
year = "2024",
month = feb,
doi = "10.1002/alz.13528",
language = "English",
volume = "20",
pages = "1166--1174",
journal = "ALZHEIMERS DEMENT",
issn = "1552-5260",
publisher = "Elsevier Inc.",
number = "2",

}

RIS

TY - JOUR

T1 - Plasma pTau-217 and N-terminal tau (NTA) enhance sensitivity to identify tau PET positivity in amyloid-β positive individuals

AU - Woo, Marcel S

AU - Tissot, Cécile

AU - Lantero-Rodriguez, Juan

AU - Snellman, Anniina

AU - Therriault, Joseph

AU - Rahmouni, Nesrine

AU - Macedo, Arthur C

AU - Servaes, Stijn

AU - Wang, Yi-Ting

AU - Arias, Jaime Fernandez

AU - Hosseini, Seyyed Ali

AU - Chamoun, Mira

AU - Lussier, Firoza Z

AU - Benedet, Andrea L

AU - Ashton, Nicholas J

AU - Karikari, Thomas K

AU - Triana-Baltzer, Gallen

AU - Kolb, Hartmuth C

AU - Stevenson, Jenna

AU - Mayer, Christina

AU - Kobayashi, Eliane

AU - Massarweh, Gassan

AU - Friese, Manuel A

AU - Pascoal, Tharick A

AU - Gauthier, Serge

AU - Zetterberg, Henrik

AU - Blennow, Kaj

AU - Rosa-Neto, Pedro

N1 - © 2023 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.

PY - 2024/2

Y1 - 2024/2

N2 - INTRODUCTION: We set out to identify tau PET-positive (A+T+) individuals among amyloid-beta (Aβ) positive participants using plasma biomarkers.METHODS: In this cross-sectional study we assessed 234 participants across the AD continuum who were evaluated by amyloid PET with [18 F]AZD4694 and tau-PET with [18 F]MK6240 and measured plasma levels of total tau, pTau-181, pTau-217, pTau-231, and N-terminal tau (NTA-tau). We evaluated the performances of plasma biomarkers to predict tau positivity in Aβ+ individuals.RESULTS: Highest associations with tau positivity in Aβ+ individuals were found for plasma pTau-217 (AUC [CI95% ] = 0.89 [0.82, 0.96]) and NTA-tau (AUC [CI95% ] = 0.88 [0.91, 0.95]). Combining pTau-217 and NTA-tau resulted in the strongest agreement (Cohen's Kappa = 0.74, CI95% = 0.57/0.90, sensitivity = 92%, specificity = 81%) with PET for classifying tau positivity.DISCUSSION: The potential for identifying tau accumulation in later Braak stages will be useful for patient stratification and prognostication in treatment trials and in clinical practice.HIGHLIGHTS: We found that in a cohort without pre-selection pTau-181, pTau-217, and NTA-tau showed the highest association with tau PET positivity. We found that in Aβ+ individuals pTau-217 and NTA-tau showed the highest association with tau PET positivity. Combining pTau-217 and NTA-tau resulted in the strongest agreement with the tau PET-based classification.

AB - INTRODUCTION: We set out to identify tau PET-positive (A+T+) individuals among amyloid-beta (Aβ) positive participants using plasma biomarkers.METHODS: In this cross-sectional study we assessed 234 participants across the AD continuum who were evaluated by amyloid PET with [18 F]AZD4694 and tau-PET with [18 F]MK6240 and measured plasma levels of total tau, pTau-181, pTau-217, pTau-231, and N-terminal tau (NTA-tau). We evaluated the performances of plasma biomarkers to predict tau positivity in Aβ+ individuals.RESULTS: Highest associations with tau positivity in Aβ+ individuals were found for plasma pTau-217 (AUC [CI95% ] = 0.89 [0.82, 0.96]) and NTA-tau (AUC [CI95% ] = 0.88 [0.91, 0.95]). Combining pTau-217 and NTA-tau resulted in the strongest agreement (Cohen's Kappa = 0.74, CI95% = 0.57/0.90, sensitivity = 92%, specificity = 81%) with PET for classifying tau positivity.DISCUSSION: The potential for identifying tau accumulation in later Braak stages will be useful for patient stratification and prognostication in treatment trials and in clinical practice.HIGHLIGHTS: We found that in a cohort without pre-selection pTau-181, pTau-217, and NTA-tau showed the highest association with tau PET positivity. We found that in Aβ+ individuals pTau-217 and NTA-tau showed the highest association with tau PET positivity. Combining pTau-217 and NTA-tau resulted in the strongest agreement with the tau PET-based classification.

U2 - 10.1002/alz.13528

DO - 10.1002/alz.13528

M3 - SCORING: Journal article

C2 - 37920945

VL - 20

SP - 1166

EP - 1174

JO - ALZHEIMERS DEMENT

JF - ALZHEIMERS DEMENT

SN - 1552-5260

IS - 2

ER -